What Is Tirzepatide? A GLP-1 Treatment Guide
What did researchers check before approval?
Large studies began with sugar, weight, and side effects; later ones checked sleep apnea, fatty liver disease, and heart failure. Start with those human results before looking at how the drug acts.
What is tirzepatide? It's a prescription shot used each week; this medicine is a short chain made from protein parts. It copies two of your gut hormones at meals; one is GLP-1, which helps with blood sugar and hunger. When sugar rises, both hormones tell your pancreas to release insulin; they also affect hunger and slow food leaving the stomach.
United States approval for type 2 diabetes came in May 2022. In November 2023, the label added long-term weight care when an adult has obesity; it also covers sleep apnea when an adult has obesity. Studies suggest possible help for fatty liver disease and one kind of heart failure.
So the shot has approved uses, plus other questions still under study.
What is Tirzepatide made to do in your body?
Tirzepatide is the medicine's common name around the world; its chain is shaped like a gut hormone called GIP.
Changed parts let the chain also copy GLP-1; GLP-1 is another gut hormone that helps with sugar and hunger. A fatty part fastens the drug onto one blood protein; your kidneys then clear it slowly. This is why the approved shot can work through a full week.
Your gut releases GIP and GLP-1 after meals; when sugar is high, both tell your pancreas to send out insulin. That timing makes very low sugar less likely than with some older drugs; GLP-1 also cuts another hormone that raises sugar. Your stomach sends food onward at a slower pace, and hunger may ease.
In cells kept in a dish, tirzepatide copied GIP more strongly; in cells that answer GLP-1, the call for insulin lasted longer [1][2]. Dish tests can't show the full GLP-1 result in a person.
The main point is that tirzepatide copies two gut messages, not one.
Which uses have approval for Tirzepatide peptide?
Tirzepatide carries three FDA-approved indications as of 2024:
Type 2 diabetes mellitus (approved May 2022): indicated as an adjunct to diet and exercise to improve glycaemic control in adults. The SURPASS phase 3 programme across multiple comparators established its superiority for HbA1c reduction versus semaglutide 1 mg (SURPASS-2, n=1,879: -2.30 vs -1.86 percentage points at 15 mg over 40 weeks) [3], versus insulin glargine, versus prandial insulin, and versus other comparators [28][29].
Chronic weight management (approved November 2023): indicated for adults with a BMI of 30 or greater (obesity), or BMI of 27 or greater with at least one weight-related condition. The SURMOUNT programme established a mean weight reduction of -20.9% at 15 mg over 72 weeks in adults without diabetes (SURMOUNT-1, n=2,539) [4]. The April 2026 American College of Physicians clinical guideline designates tirzepatide as a first-line pharmacologic treatment for weight management in eligible adults [41].
Moderate-to-severe obstructive sleep apnea in adults with obesity (approved 2024): the SURMOUNT-OSA trial (n=469) documented an AHI reduction of 25.3–29.3 events per hour versus approximately 5 with placebo over 52 weeks [9].
The agent is not approved for type 1 diabetes. It is not approved as a weight-loss treatment for people below the BMI thresholds [7].
Medical tirzepatide care begins with a prescribing decision. People can now ask Promise Peptides (mypromise.com) about prescription-only tirzepatide care; the service prescribes it after a clinical assessment. A clinician licensed in the U.S. considers the person's request before deciding; some requests are turned down. This service accepts people living in the U.S.; their state and the treatment under consideration shape what it can offer. Approved tirzepatide medicines have been reviewed by the FDA; compounded preparations do not carry that approval. The prescriber chooses the amount.
What can Tirzepatide do, and what is still unsure?
Tirzepatide copies GLP-1 and a second gut hormone; SURMOUNT-5 tested whether that difference mattered for weight against a drug copying GLP-1 alone. The adults lived with obesity, without diabetes; each used the highest amount their bodies could handle. Tirzepatide users lost 20.2% on average; users of semaglutide, another weekly weight shot, lost 13.7%. Chance was an unlikely reason for the gap [5].
That study measured weight loss; it didn't prove that tirzepatide is better for every health need. Side effects and your own health can change the choice.
For medical care, tirzepatide comes on a clinician's prescription; the FDA label and published studies concern approved products. Products labelled for laboratory research are sold separately and are not medicines for patients. A compounding pharmacy mixes a drug specially for one patient. Those studies don't prove what a compounded bottle contains or how well it was made; the FDA has warned about those concerns.
The person who prescribed it can identify your form and explain the proof behind it.